Določanje klona PNH. Darja Žontar, Specializirani laboratorij KOH, UKC Ljubljana
|
|
- Ambrose Parrish
- 5 years ago
- Views:
Transcription
1 Določanje klona PNH Darja Žontar, Specializirani laboratorij KOH, UKC Ljubljana
2 Paroksizmalna nočna hemoglobinurija Edina pridobljena hemolitična anemija zaradi napake v eritrocitni membrani Klonska bolezen: eritroci, trombociti in granulociti izvirajo iz iste, z mutacijo spremenjene matične celice; mutacija X-vezanega PIG-A gena povzroči delno ali popolno pomanjkanje proteinov, ki so vezani na celično membrano z glikozilfosfatidilinozitolnim sidrom (GPI) Povečana dovzetnost za litični učinek koplementa-razpad eritrocitov Dve populaciji eritrocitov-normalna in z napako v membrani Stopnja hemolize odvisna od razmerja med njima
3 PNHEU11002/NECMEA-eng01 The Defect in PNH with the courtesy of Alexion Pharmaceuticals The Somatic Mutation of the PIG A gene prevents all GPI anchored proteins from binding to cell surface CD59 Forms a defensive shield for RBCs from complement-mediated lysis1 Inhibits the assembly of the membrane attack complex CD55 Prevents formation and augments instability of the C3 convertases, attenuating the complement cascade2 CD59 GPI-anchor CD55 GPI - Glycosylphosphatidylinositol; PIG A - phosphatidylinositol glycan anchor biosynthesis A 1. Johnson RJ et al. J Clin Pathol: Mol Pathol 2002;55: Brodsky R. Paroxysmal Nocturnal Hemoglobinuria. In: Hematology - Basic Principles and Practices. 4th ed. R Hoffman; EJ Benz; S Shattil et al. eds. Philadelphia, PA: Elsevier Churchill Livingstone; 2005; pp
4
5 Laboratorijske preiskave za dokaz PNH klona Hamov test (kisli serum test), Sugar-water test Pretočna citometrija-monoklonska protitelesa Prva: CD55 DAF (decay acceleration factor) CD59-MIRL (membrane inhibitor of reactive lysis) FLAER (Fluorescent Labeled AERolysin) Inaktiviran bakterijski toksin se veže direktno na GPI-sidra ; samo na granulocitih in monocitih
6 Antibodies to transmembrane proteins are used to gate on various WBC populations. PNH clones are then detected with antibodies to GPI-proteins (and FLAER) GPI-AP Antibodies like CD55, CD59, CD24, CD16, CD66b and CD14 bind indirectly to the GPI anchor FLAER FLAER binds directly to the GPI anchor Kumar: Robbins and Cotran: Pathologic Basis of Disease, 7th ed. Fig with the courtesy of Alexion Pharmaceuticals 6
7 Ugotavljaje prisotnosti PNH klona s pretočno citometrijo Granulociti-najzanesljivejši za dokaz PNH klona Monociti-potrjujejo PNH klon na granulocitih (klon pogosto večji kot na granulocitih; natančnost manjša zaradi manjšega števila) Limfociti-niso primerni za testiranje zaradi drugačne življenske dobe; le za notranjo kontrolo protiteles Eritrociti-primerni za oceno velikosti klona, ki pa lahko variira zaradi hemolize ali transfuzije 7
8 Izbor protiteles za PNH analize Lab-specific PNH Panels with GPI-linked antibodies and/or FLAER CD55 CD59 CD16 CD66b CD24 CD14 FLAER RBC - ++ NA NA NA NA NA Gran? NA ++ Monos? - NA NA NA Very good Signal/noise ratio + Moderate signal/noise ratio - not recommended Staining with FLAER has become the method of choice as it appears to be a more sensitive and specific method to detect PNH clones in WBCs 1. Borowitz MJ et al. for the International Clinical Cytometry Society. Cytometry B Clin Cytom 2010;78B: with the courtesy of Alexion Pharmaceuticals 8
9 Priprava vzorcev za analizo 2 epruveti za 4-barvno analizo na nevtrofilnih granulocitih in monocitih 100 µl dobro premešane venske krvi inkubiramo s protitelesi minut v temi pri sobni T. Eritrocite liziramo z Immunoprep reagentom, dvakrat speremo s PBS in resuspendiramo v 0,5 ml PBS. Nevtrofilne granulocite zamejimo s FS/SS/CD45/CD15 in monocite s FS/SS/CD45/CD64 ), analiziramo granulocitov (ciljna občutljivost 0.1%) in določimo PNH klone s FLAER v kombinaciji s CD24 na granulocitih in CD14 na monocitih. Kot klon opredelimo samo dvojno negativno populacijo. 1 epruveta za 2-barvno analizo na eritrocitih: 50 µl predhodno razredčene venske krvi (10 µl polne krvi + 1 ml PBS) inkubiramo s predhodno razredčeno in titrirano kombinacijo protiteles CD235a-FITC in CD59-PE za 30 minut v temi pri sobni T, dvakrat speremo s PBS in resuspendiramo v 0,5 ml PBS Eritrocite zamejimo z logfs/logss/cd235a in analiziramo celic (ciljna občutljivost 0.1%). PNH klon opredelimo kot tip III (povsem negativen CD59) ali tip II (delno negativen CD59).
10
11 PNH klon na nevtrofilnih granulocitih
12 PNH klon na monocitih
13 PNH klon na nevtrofilnih granulocitih
14 PNH klon na monocitih
15 Vzorec s pomikom v levo v DKS
16 Določanje PNH klona na eritrocitih CD59:izražen v visoki stopnji, označuje tip I, II in III eritrocitov CD55: slabše izražen, pogosto ne označuje tipa II eritrocitov (uporaba se opušča) Anti-Glycophorin A (CD235a): specifičen za označevanje eritroctov Določanje v polni krvi z predhodno razredčenimi protitelesi, da se izognemo agregatom
17 August_12_2010Gbl 17
18 PNHEU11002/NECMEA-eng01 Count Testing for PNH in Red Blood Cells - CD59 plus CD235a Type III 0.0% Type II 0.0% Type I 100% Normal RBCs with normal CD59 expression (Type I cells) CD59-PE Type III 6% Type II 0.1% Type I 93.9% PNH clone with complete CD59 deficiency (Type III cells) CD59-PE CD59-PE Gating on GPA+ RBCs Type III 11.9% Type II 71.3% Type I 16.8% PNH clone with complete CD59 deficiency (Type III cells) and partial CD59 deficiency (Type II cells) CD59-PE GPA: glycophorin A 1. Borowitz MJ et al. for the International Clinical Cytometry Society. Cytometry B Clin Cytom. 2010;78B:
19
20 Različni fenotipi eritrocitov pri PNH SJ Richards et al, Cytometry 42: , 2000
21 PNH eritrociti tipa II in III
22 PNH eritrociti tipa II in III
23 PNHEU11002/NECMEA-eng01 CD24-Granulocytes Important to Monitor Granulocytes and RBCs Over Time 1 Sept 08 Dec 08 Mar 09 May 09 Granulocytes: 3.8% FLAER-GPI Anchor Marker Granulocytes: 7.6% Granulocytes: 14.2% Granulocytes: 23.3% RBCs: 0.8% RBCs : 1.6% RBCs : 1.8% RBCs : 2.4% CD59 GPI Anchor Protein 3 months 6 months 9 months PNH clone expanded in < 1 year 1. Adapted with permission from Dahl-Chase Diagnostic Services. 23
24 Smernice I Guidelines for the diagnosis and monitoring of Paroxysmal Nocturnal Hemoglobinuria and related disorders by flow cytometry Borowitz MJ et al. Cytometry Part B 2010; 78: Poudariti klinični pomen določanja PNH klona s pretočno citometrijo Določiti klinične indikacije za PNH analize Izbrati enoten pristop k PNH analizam s priporočenim izborom protiteles za določanje na granulocitih, monocitih in eritrocitih
25 Smernice II Practical Guidelines for the High-Sensitivity Detection and Monitoring of Paroxysmal Nocturnal Hemoglobinuria Clones by Flow Cytometry Sutherland DR, Keeney M, Illingworth A. Cytometry Part B 2012; 82B: Dokument, ki dopolnjuje smernice ICCS iz leta 2010 Zagotavlja dragocene informacije o GPI vezanih protitelesih in linijsko specifičnih protitelesih za PNH testiranje in priporoča specifične koktajle protiteles za optimalno analizo Zagotavlja zgoščene praktične protokole za visoko občutljivo metodo odkrivanja PNH eritrocitov, nevtrofilnih granulocitov in monocitov
26 Study- part of Alexion s PNH Dx network approach 1. Lab training 2. Normal blood testing 3. PNH blood testing 4. Lab certification FC training (expert) Discuss PNH panel required (expert) Provide PNH testing panel (Alexion) PNH testing with normal blood (lab) Validation of testing results (expert) PNH testing of pathological samples Validation of positive PNH testing results (expert) Interlaboratory testing of PNH samples Validation of interlaboratory testing results (expert) Lab certification for PNH testing (expert)
27 Participants IHBT-Prague: reference center FH-Plzen: center 1 FH-Brno: center 2 IO-Bratislava: center 3 UMC-Ljubljana: center 4 Andrea Illingworth, Dahl-Chase Diagnostic Services, USA: on-site PNH testing workshop following ICCS guidelines and support Alexion Pharma International: coordination and financial support
28 Ponovljivost: PNH kloni na eritrocitih tipa III in tipov II in III skupaj 5x ponovljeno pipetiranje in označevanje v vsakem vzorcu Dr. Iuri Marinov, UHKT, Praga
29 Ponovljivost : PNH kloni na nevtrofilnih granulocitih in monocitih 5x ponovljeno pipetiranje in označevanje v vsakem vzorcu Dr. Iuri Marinov, UHKT, Praga
30 Natančnost: PNH kloni na eritrocitih tipa III in tipih II+III skupaj Dr. Iuri Marinov, UHKT, Praga
31 Natančnost : PNH kloni na nevtrofilnih granulocitih in monocitih Dr. Iuri Marinov, UKHT, Praga
32 Podajanje rezultatov > 1% = PNH klon 0,1% - 1% = mali klon ali populacija PNH celic < 0,1% = posamezne celice z znižanimi GPI označevalci 32
33 Zaključki Metoda določanja PNH klona s pretočno citometrijo je zlati standard Določanje PNH klona na nevtrofilnih granulocitih je najboljša metoda za opredelitev velikosti PNH klona Določanje PNH klona na eritrocitih ni zadostno za oceno velikosti klona, je pa koristna informacija FLAER je verjetno najboljši reagent za dokaz PNH klona na levkocitih
9/19/2017. PNH Understanding your diagnosis and treatment. Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria
August_20_2010US Patients Surviving (%) Paroxysmal Nocturnal Hemoglobinuria (PNH) PNH Understanding your diagnosis and treatment Hugo Castro-Malaspina, MD Memorial Sloan Kettering Cancer Center New York,
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationJasmina Hauptman, Darja Žontar, Irena Preložnik Zupan. Podčetrtek,
Jasmina Hauptman, Darja Žontar, Irena Preložnik Zupan Podčetrtek, 4.4.2013 Gre za življenje ogrožujočo bolezen, ki lahko vodi do kronične okvare organov ter prezgodnjo smrt, predvsem zaradi tromboz ali
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationSponsored and reviewed by ICCS Quality and Standards Committee Title: Verification of PNH assay sensitivity through spiking experiment Written by:
Sponsored and reviewed by ICCS Quality and Standards Committee Title: Verification of PNH assay sensitivity through spiking experiment Written by: A Illingworth, T Oldaker, R Sutherland, S Kotanchiyev,
More informationPNH. What is PNH? 7/12/2016 PNH. What is PNH? 1 st published case report of PNH
AA-MDS Patient Conference Raleigh / Durham July 016 : Current Thinking on the Disease, Diagnosis, and Treatment What is? What causes? What are the clinical symptoms of? How is diagnosed? What are the long-term
More information9/19/2012. Case study. Case study PNH: A REVIEW AND AN UPDATE
PNH: A REVIEW AND AN UPDATE Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Case study A 37 year old man was referred to the hematology
More informationHow to diagnose myeloproliferative neoplasms and PNH in vascular diseases of the liver Valerio De Stefano
How to diagnose myeloproliferative neoplasms and PNH in vascular diseases of the liver Valerio De Stefano Institute of Hematology, Catholic University School of Medicine, Academic Hospital A. Gemelli,
More informationPripravki levkocitov. Dr. Dragoslav Domanovič, dr.med. Zavod RS za transfuzijsko medicino Ljubljana
Pripravki levkocitov Dr. Dragoslav Domanovič, dr.med. Zavod RS za transfuzijsko medicino Ljubljana Razdelitev levkocitov Granulociti polimorfonuklearni levkociti Nevtrofilci Bazofilci Eozinofilci Agranulociti
More informationWhat is PNH? PNH: What it is Not 9/11/2015. What is Paroxysmal Nocturnal Hemoglobinuria?
9/11/15 PNH: Current Thinking on the Disease, Diagnosis, and Treatment Joseph H. Antin, MD Professor of Medicine Harvard Medical School Jock and Bunny Adams Chair in Hematology Dana-Farber/Brigham and
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationWelcome. Welcome. Emerging Technologies in Flow Cytometry
Emerging Technologies in Flow Cytometry Dr. William Dittman December 11, 2012 You may download a copy of the handout by clicking on the handout icon, located in the upper right hand corner of your screen
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2018 Clinical Consequences of Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia: A Multidisciplinary Discussion PLUS
More informationKey terms: aplastic anemia; complement inhibitors; paroxysmal nocturnal hemoglobinuria
Cytometry Part B (Clinical Cytometry) 94B:16 22 (2018) Original Article ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders
More information3/31/2014 PNH. Jack Goldberg MD FACP. Clinical Professor of Medicine University of Pennsylvania
PNH Jack Goldberg MD FACP Clinical Professor of Medicine University of Pennsylvania 1 2 3 4 1 5 6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by
More informationAbdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report
Received: 22 January 2018 Revised: 25 April 2018 DOI: 10.1002/ccr3.1771 Accepted: 9 June 2018 CASE REPORT Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for
More informationPNH PNH PNH 3/22/2016 PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH): Current Thinking on the Disease PATHOGENESIS OF PNH
3//1 PATHGENESIS F PIG-A gene Bone Marrow Failure Disease Scientific Symposium Rockville, March 17-1, 1 1 71 9 3 Paroxysmal Nocturnal Hemoglobinuria (): Current Thinking on the Disease 119 5 15 PRTEIN
More informationDiagnosing PNH with FLAER and Multiparameter Flow Cytometry
Cytometry Part B (Clinical Cytometry) 72B:167 177 (2007) Original Articles Diagnosing PNH with FLAER and Multiparameter Flow Cytometry D. Robert Sutherland, 1 * Nancy Kuek, 1 Jeff Davidson, 1 David Barth,
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2014 (2014), Article ID 504318, 21 minipages. DOI:10.5171/2014.504318 www.ibimapublishing.com Copyright 2014 Pinar Tosun Taşar, Sevnaz Sahin, Asu
More information10/27/2017 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DANIEL LANDAU, MD PNH TYPICAL CASE
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Daniel Landau, MD Orlando Health: UF Health Cancer Center Hematologist/ Oncologist Orlando Health University of Florida Cancer Center Section Chief of Hematology/Oncology
More informationClinico-cytometric classification of PNH
Clinico-cytometric classification of PNH Definition Clone size (by FCM) Hemolysis BMF Classic (or florid) Large + - PNH in the setting of other BM disorders Small, unable to counterbalance BMF + + Subclinical
More informationPNH. PNH A study case 5/9/2012. PNH Current Thinking on the Disease, Diagnosis, and Treatment. Where have we been, where are we going?
PNH Current Thinking on the Disease, Diagnosis, and Treatment Where have we been, where are we going? Carlos M. de Castro, MD Duke University Medical Center PNH Case What is PNH? What causes PNH? Relationship
More information1/26/12. Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY OBJECTIVES. Classically Different Topics but not so much
1/26/12 OBJECTIVES Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY Chatchawin Assanasen MD Recognize implications of complement pathway diseases Signs and symptoms of PNH and ahus Complications
More informationParoxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis
September 2013 Volume 11, Issue 9, Supplement 13 Paroxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis Plus a Case Report and a Q&A on the Role of the Hematopathologist Vivek R. Sharma,
More information5/21/2018. PNH: Understanding Your Disease and Treatment Options
Patients Surviving (%) 5/2/28 PNH: What s in a Name PNH: Understanding Your Disease and Treatment Options Bart Scott, MD Associate Professor of Medicine, Division of Oncology, University of Washington
More information7/26/2013. The Defect in PNH PNH: NEW DIRECTIONS IN PNH TREATMENT. Paroxysmal Nocturnal Hemoglobinuria: Survival
PNH: NEW DIRECTIONS IN PNH TREATMENT Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Paroxysmal Nocturnal Hemoglobinuria: Survival
More informationNew Insights into Paroxysmal Nocturnal Hemoglobinuria
New Insights into Paroxysmal Nocturnal Hemoglobinuria Robert A. Brodsky Johns Hopkins University School of Medicine, Division of Hematology, Baltimore, MD Correspondence: Robert A. Brodsky, MD, Ross Research
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Jun Ho Jang, M.D., Ph.D. Professor, Division of Hematology-Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea Contents 1. Disease
More informationPNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy
PNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy PI: Prof. Anna Falanga Bergamo Italy Prof. Anna Falanga Page 1of 9 Introduction Scientific background Genetic basis
More informationNew Phase III Clinical Trial Enrolling Now
New Phase III Clinical Trial Enrolling Now Paroxysmal Nocturnal Hemoglobinuria (PNH) Designed for Patients 1. At least 18 years of age 2. With a primary diagnosis of PNH confirmed by high-sensitivity flow
More informationTube 1 : FLAER/CD24/CD16/CD15/CD45
Gating procedure for white blood cells (WBC) on FC500 The French PNH diagnosis working group has developed an optimized gating strategy adapted to a two-tubes diagnostic test (PMN, MO), evaluated in a
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Current Thinking On the Disease Diagnosis and Treatment Ilene Ceil Weitz, MD Associate Clinical Professor of Medicine Jane Anne Nohl Division of Hematology Keck-USC
More informationDo Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine
Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity
More informationAcknowledgments. Michael Brown Petra Muus for case reports
Current treatment strategy for PNH Jeff Szer Professor/Director, Department of Clinical Haematology & BMT Service The Royal Melbourne Hospital Australia Acknowledgments Michael Brown Petra Muus for case
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationHEMATOPATHOLOGY SUMMARY REPORT RL;MMR;
HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with
More informationCASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report
Malaysian J Pathol 2006; 28(2) : 107 112 CASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report R Z Azma, MBBS,
More informationPNH: Current Thinking on the Disease, Diagnosis and Treatment. What is PNH? 7/6/2009. Paroxysmal sudden onset Nocturnal
PNH: Current hinking on the Disease, Diagnosis and reatment Jaroslaw Maciejewski, MD, PhD Cleveland Clinic Carlos M. de Castro, MD Duke University Medical Center Paroxysmal sudden onset Nocturnal occuring
More information? Medical mystery? A case report
? Medical mystery? A case report N. Boeckx, MD, PhD 03-10-2017 Case report 34 year male Medical history (Peru) 2014: anemia (Hb 7-8 g/dl) => endoscopy: negative, R/ iron April 2015: acute cholecystitis
More informationGINKGO BILOBA IN MISELNE SPOSOBNOSTI. Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015
GINKGO BILOBA IN MISELNE SPOSOBNOSTI Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015 KLINIČNO VPRAŠANJE Ali uporaba standardiziranih pripravkov Ginkgo bilobe izboljšuje
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationParoxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life-Threatening Disease. Actuarial Survival From the Time of
PNH Current Thinking on the Disease, Diagnosis, and Treatment Bart Scott, MD Associate Professor of Medicine, Division of Oncology, University of Washington Associate Member, Fred Hutchinson Cancer Research
More informationInflammation. (4 of 5)
Inflammation (4 of 5) What will we discuss today? Plasma protein derived mediators Anti-inflammatory mediators Morphologic patterns of acute inflammation Plasma protein derived mediators 3 systems: -Complement
More informationDana Alsulaibi. - Ahmad Almuhtaseb. - Tariq Al - Adaily
- 2 - Dana Alsulaibi - Ahmad Almuhtaseb - Tariq Al - Adaily This sheet will talk about 4 diseases that cause hemolytic anemia, best of luck! 1) Hereditary Spherocytosis Transferred through inheritance
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More informationComment devenir CCA en un WE? HPN aplasie médullaire
Comment devenir CCA en un WE? HPN aplasie médullaire Régis Peffault de Latour, MD, PhD Saint Louis Hospital, Paris; regis.peffaultdelatour@sls.aphp.fr AIH 27 Septembre 2014 Paroxysmal Nocturnal Hemoglobinuria
More informationParoxysmal Nocturnal Hemoglobinuria And Related Disorders Molecular Aspects Of Pathogenesis Softcove
Paroxysmal Nocturnal Hemoglobinuria And Related Disorders Molecular Aspects Of Pathogenesis Softcove PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RELATED DISORDERS MOLECULAR ASPECTS OF PATHOGENESIS SOFTCOVE
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationALXN 1210 for paroxysmal nocturnal haemoglobinuria first line
NIHR Innovation Observatory Evidence Briefing: November 2017 ALXN 1210 for paroxysmal nocturnal haemoglobinuria first line NIHRIO (HSRIC) ID: 12793 NICE ID: 9701 LAY SUMMARY Paroxysmal nocturnal haemoglobinuria
More informationGetting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation.
Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation. Sysmex America White Paper One Nelson C. White Parkway,
More informationAcute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration
Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration Chun-Liang Lin 1, Chin-Chan Lin 1,Wen-Jyi Lo 2,Yu-Chien
More informationRelationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored proteindeficient
British Journal of Haematology, 2001, 115, 1015±1022 Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored proteindeficient clones Jaroslaw P. Maciejewski,
More informationHEMATURIJA PRI OTROCIH HAEMATURIA IN CHILDREN
HEMATURIJA PRI OTROCIH HAEMATURIA IN CHILDREN - ABSTRACT - - UVOD IN OPREDELITEV POJMOV Hematurija je prisotnost krvi v urinu. - - - mesecev. Lahko je - - Hematurija je sicer lahko pomemben znak bolezni
More informationTarget cell lysis Opsonization Activation of the inflammatory response (e.g. degranulation, extravasation) Clearance of immune complexes
Immunology Dr. John J. Haddad Chapter 13 Complement Major roles of complement (Figure 13-1): Target cell lysis Opsonization Activation of the inflammatory response (e.g. degranulation, extravasation) Clearance
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationAltered Expression Pattern of CD55 and CD59 on Red Blood Cells in Anemia of Chronic Kidney Disease
Original Paper Received: November 21, 2016 Accepted: September 28, 2017 Published online: September 28, 2017 Altered Expression Pattern of CD55 and CD59 on Red Blood Cells in Anemia of Chronic Kidney Disease
More informationEffect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
The new england journal of medicine original article Effect of on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, M.B., Ph.D., Claire Hall, M.B.,
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More information4/17/2018. Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria. Epidemiology. PNH Stem Cell.
Paroxysmal Nocturnal Hemoglobinuria: Understanding the Diagnosis, Complications and Treatment Options Iberia Romina Sosa, MD, PhD Assistant Professor of Medicine Baylor College of Medicine April 21, 2018
More informationJunfeng Wang 12/10/2010
Paroxysmal Nocturnal Hemoglobinuria. Junfeng Wang 12/10/2010 31 Year Old Female with 11-year History of PNH In 1989, she presented with bleeding & pancytopenia. BM x2 showed AA. Cytogenetic ti was normal.
More informationWHITE PAPER IMMATURE GRANULOCYTE (IG) POPULATIONS MAY IMPROVE THE ASSESSMENT OF INFECTION AND SEPSIS. Getting beyond the flags.
WHITE PAPER IMMATURE GRANULOCYTE (IG) POPULATIONS MAY IMPROVE THE ASSESSMENT OF INFECTION AND SEPSIS. Getting beyond the flags www.sysmex.com/us Introduction For many decades, physicians have relied on
More informationName: Factor H Catalog Number: A137 Sizes Available: Concentration: Form: Activity: Purity: Buffer: Extinction Coeff.: Molecular weight:
Name: Factor H Catalog Number: A137 Sizes Available: 250 µg/vial Concentration: 1.0 mg/ml (see Certificate of Analysis for actual concentration) Form: Frozen liquid Activity: >90% versus normal human serum
More informationpersistent low-level PNH that predated and possibly contributed to the development
Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes Why? Why? Why? Commentary See related article, pages 689 696. Neal S. Young and Jaroslaw P. Maciejewski
More informationLaboratory Medicine Pulse
The Newsletter of the Department of Pathology Feinberg School of Medicine and Northwestern Memorial Hospital Volume 3, Issue 3 SPRING 2016 Newsletter Editor in chief Inside this issue: Paroxysmal Nocturnal
More informationHematopoietic Progenitor Cells in the Blood and Bone Marrow in Various Hematolorric Disorders
Hematopoietic Progenitor Cells in the Blood and Bone Marrow in Various Hematolorric Disorders SURAPOL ISSARAGKISIL, YAOWALAK U-PRATYA, MANEENOP YIMYAM, KRIANGSAK PAKDEESUWAN, ARCHROB KHUHAPINANT, WANNA
More informationSoliris (eculizumab) For the Treatment of PNH to Reduce Hemolysis
Soliris (eculizumab) You have done well to manage your PNH with Soliris. Living with a rare disease, like PNH, can be challenging, but by sticking with your Soliris therapy, you are doing a lot to help
More informationParoxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine Phillip Scheinberg, Michael Marte, Olga Nunez, and Neal S. Young
More information7/14/2014. SOLIRIS (eculizumab) SOLIRIS PNH Clinical Studies. SOLIRIS Blocks Terminal Complement. 86% Reduction in LDH: TRIUMPH and SHEPHERD
Proximal Terminal Lactate Dehydrogenase (U/L) 7/1/1 SOLIRIS (eculizumab) Humanized First in Class Anti - C5 Antibody SOLIRIS (eculizumab) Human Framework Regions No mutations Germline SOLIRIS is a Complement
More informationClinical significance of a minor population of paroxysmal nocturnal hemoglobinuria type cells in bone marrow failure syndrome
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria type cells in bone marrow failure syndrome Hongbo Wang, Tatsuya
More informationSOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis
SOLIRIS (eculizumab) SOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis SOLIRIS is the First and Only Approved Therapy for PNH SOLIRIS (eculizumab) [package
More informationUnderstanding and Managing Long- Term and Late Issues in PNH. Outline
Understanding and Managing Long- Term and Late Issues in PNH AA & MDS International Foundation Regional Patient and Family Conference Cleveland, Ohio Ramon V. Tiu, MD Cleveland Clinic Taussig Cancer Institute
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationMINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS
Tuesday, July 24th, 10:30 MINISYMPOSIUM MATHEMATICAL MODELING OF LEUKEMIA AND MYELOPROLIFERATIVE NEOPLASMS Organizer Morten Andersen Roskilde University Denmark moan@ruc.dk Co-organizer Thomas Stiehl Heidelberg
More informationParoxysmal nocturnal hemoglobinuria (PNH) has been a
Neutral evolution in paroxysmal nocturnal hemoglobinuria David Dingli a,1, Lucio Luzzatto b,c, and Jorge M. Pacheco d a Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905; b
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
The Oncologist Regulatory Issues: FDA FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria ANDREW DMYTRIJUK, KATHY ROBIE-SUH, MARTIN H. COHEN, DWAINE
More informationWARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. WARNING:
More informationIF YOU HAVE PNH, YOU ARE NOT ALONE. Take a closer look and take control of PNH
IF YOU HAVE PNH, YOU ARE NOT ALONE Take a closer look and take control of PNH Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients
More informationComplement deficiencies, diagnosis and management. Contents
Complement deficiencies, diagnosis and management Classification: Protocol Lead Author: Dr Hana Alachkar Additional author(s): Victoria Blakeley Authors Division: Tertiary Medicine Unique ID: D5 Issue
More informationSlika 1: Vzorci zemlje
DELOVNI LIST INŠTITUT HAIDEGG Inštitut Haidegg je inštitut za raziskavo zemlje oz. tal. Bili so prvi, ki so leta 1987 pričeli z raziskavami. Od leta 2006 jemljejo vzorce na 1000 različnih mestih po Avstriji.
More informationTransforming Complement Therapeutics. June 2018
Transforming Complement Therapeutics June 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria Andrew Dmytrijuk, Kathy Robie-Suh, Martin H. Cohen, Dwaine Rieves, Karen Weiss and Richard Pazdur
More informationSupplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated
1 Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated (U) EGFR TL mice (n=7), Kras mice (n=7), PD-1 blockade
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More informationComparison of erythrocyte and reticulocyte indices for the diagnosis of iron deficiency
Comparison of erythrocyte and reticulocyte indices for the diagnosis of iron deficiency Primerjava eritrocitnih in retikulocitnih parametrov pri ugotavljanju pomanjkanja železa Eva Jarc, 1 Irena Preložnik
More informationCleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationTransforming Complement Therapeutics. August 2018
Transforming Complement Therapeutics August 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
More informationAurin Tricarboxylic Acid Protects against Red Blood Cell Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinemia
Aurin Tricarboxylic Acid Protects against Red Blood Cell Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinemia Moonhee Lee 1, Sujaatha Narayanan 2, Edith G. McGeer 1, Patrick L. McGeer 1 * 1 Kinsmen
More informationCPAL and GenPath Flow Cytometry Specimen Handling
CPAL and GenPath Flow Cytometry Specimen Handling Lmphocyte Subset Analysis Peripheral Blood Bone Marrow Aspirates Surgical Biopsies Fine Needle Aspirate Biopsies Fluids Cerebral Spinal Fluid Bronchial
More informationTopic (6): The Complement System
Topic (6): The Complement System Introduction The complement system is a complex system of many different glycoproteins. It comprises several plasma proteins that sequentially activate each other by proteolytic
More informationHEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC
HEMOLYTIC ANEMIAS Edited by: GR. Bahoush, MD. HEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC destruction
More informationThe Relationship of Aplastic Anemia and PNH
HEMATOLOGY The Relationship of Aplastic Anemia and PNH Neal S. Young, Jaroslaw P. Maciejewski, Elaine Sloand, Guiben Chen, Weihua Zeng, Antonio Risitano, and Akira Miyazato Hematology Branch, National
More informationTransforming Complement Therapeutics. October 2018
Transforming Complement Therapeutics October 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationTheme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -
Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects - Professor Yutaka YATOMI, M.D., Ph.D., The Department of Clinical Laboratory Medicine,
More informationGlycans linked to lipids and lipid precursors
Glycobiology BCMB 8130 Clinical Correlations! -sign up for 1st and 2nd choice (1/2)! *********************************! Glycosylation in Diabetes! O-Mannosylation in Human Pathophysiology! Glycoconjugate
More informationBIOS222 Pathology and Clinical Science 2
BIOS222 Pathology and Clinical Science 2 Session 3 Lymphatic and Haematological Disorders 1 Bioscience Department www.endeavour.edu.au Session Learning Outcomes At the end of this session, you should be
More informationM1 - Immunology, Winter 2008
University of Michigan Deep Blue deepblue.lib.umich.edu 2008-09 M1 - Immunology, Winter 2008 Fantone, J.; Pietropaolo, M. T. Fantone, J., Pietropaolo, M. T. (2008, August 13). Immunology. Retrieved from
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Soliris (eculizumab) Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Soliris (eculizumab) Prime Therapeutics will review Prior Authorization requests
More informationName: C5 Protein Catalog Number: A120 Sizes Available: Concentration: Form: Activity: Purity: Buffer: Extinction Coeff.
Name: C5 Protein Catalog Number: A120 Sizes Available: 250 µg/vial Concentration: 1.0 mg/ml (see Certificate of Analysis for actual concentration) Form: Frozen liquid Activity: >80% versus normal human
More information